SAN DIEGO, Feb. 26 /PRNewswire/ -- BioVascular, Inc., a company focused on developing novel therapies targeting platelet-mediated diseases, today announced that it appointed Christopher M. Bussineau, Ph.D., to the position of vice president of pharmaceutical operations and Eric Karpinski to the position of vice president, business development and nonvascular operations.
"Dr. Bussineau and Mr. Karpinski each bring skill and experience to BioVascular that will allow us to advance our business objectives," said John Parrish, CEO of BioVascular. "With continuing clinical progress in our two compounds, we will be looking to Mr. Karpinski to advance partnership discussions. Dr. Bussineau will be invaluable for establishing the infrastructure needed for further clinical development and eventual commercialization."
Dr. Bussineau brings relevant experience to BioVascular in the areas of process development as well as clinical and commercial manufacturing. Prior to joining BioVascular, Dr. Bussineau served as vice president and general manager of Cambrex Bio Science Baltimore. Before that, he was senior director of technical operations for the Biopharmaceutical Division of Chiron Corporation, acquired by Novartis in 2006. Dr. Bussineau holds a Ph.D. in chemical engineering from Rice University and a B.A. in chemistry from the University of California, San Diego.
Mr. Karpinski has extensive experience in business development, venture
financing and strategic planning in the biopharma industry. He joined
BioVascular after six years as a venture capitalist with Forward Ventures
where he drove the diligence and supported companies in the portfolio
including Hypnion, sold to Eli Lilly for $315M; Novacardia, sold to Merck
for $350M; Predix, sold to Epix Medical; and Adiana, sold to Cytyc. Prior
to working at Forward Ventures, Mr. Karpinski held business development and
strategic planning roles at Genentech, Epix Medical and the pharmaceutical
|SOURCE BioVascular, Inc.|
Copyright©2008 PR Newswire.
All rights reserved